(Q37690991)

English

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors (English)

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

allosteric inhibitor

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Charles Swanton

object named as

Charles Swanton

2

0 references

author name string

Clifford Hudis

1

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Yelena Y Janjigian

3

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Ray Lee

4

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Stephanie Sutherland

5

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Robert Lehman

6

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Sarat Chandarlapaty

7

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Nicola Hamilton

8

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Devika Gajria

9

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

James Knowles

10

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Jigna Shah

11

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Keith Shannon

12

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Ernestina Tetteh

13

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Daniel M Sullivan

14

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Carolina Moreno

15

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Li Yan

16

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Hyo Sook Han

17

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

19 November 2013

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Breast Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

15

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

R110

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

https://scigraph.springernature.com/pub.10.1186/bcr3577

0 references

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

23 August 2017

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

23 August 2017

Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

23 August 2017

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

23 August 2017

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

23 August 2017

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

23 August 2017

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

23 August 2017

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

23 August 2017

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

23 August 2017

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

23 August 2017

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

23 August 2017

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

23 August 2017

HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

23 August 2017

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

6 September 2017

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

6 September 2017

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

1 September 2018

Dose-finding in phase I clinical trials based on toxicity probability intervals.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

1 September 2018

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3979046

1 September 2018

Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression

1 reference

https://api.crossref.org/works/10.1186%2FBCR3577

21 January 2018

Targeted cancer therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24252402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/BCR3577

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37690991&oldid=1723223515"